

Mary Ramsay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10660411/publications.pdf>

Version: 2024-02-01

43
papers

10,353
citations

212478

28
h-index

299063

42
g-index

48
all docs

48
docs citations

48
times ranked

14333
citing authors

#	ARTICLE	IF	CITATIONS
1	Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. <i>Journal of Infection</i> , 2022, 84, 675-683.	1.7	87
2	Disease severity during SARS-CoV-2 reinfection: a nationwide study. <i>Journal of Infection</i> , 2022, 84, 542-550.	1.7	49
3	Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. <i>New England Journal of Medicine</i> , 2022, 386, 340-350.	13.9	501
4	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. <i>Lancet, The</i> , 2022, 399, 36-49.	6.3	161
5	Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. <i>New England Journal of Medicine</i> , 2022, 386, 1532-1546.	13.9	1,709
6	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.. <i>Journal of Infection</i> , 2022, 84, 795-813.	1.7	43
7	Transmission dynamics of COVID-19 in household and community settings in the United Kingdom, January to March 2020. <i>Eurosurveillance</i> , 2022, 27, .	3.9	16
8	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. <i>Lancet Respiratory Medicine, the</i> , 2022, 10, 1049-1060.	5.2	24
9	Impact of Extending the Timing of Maternal Pertussis Vaccination on Hospitalized Infant Pertussis in England, 2014-2018. <i>Clinical Infectious Diseases</i> , 2021, 73, e2502-e2508.	2.9	17
10	Seropositivity and risk factors for SARS-CoV-2 infection in staff working in care homes during the COVID-19 pandemic. <i>Journal of Infection</i> , 2021, 82, 84-123.	1.7	3
11	Impact of a nurse-led enhanced monitoring, management and contact tracing intervention for chronic hepatitis B in England, 2015-2017. <i>Journal of Viral Hepatitis</i> , 2021, 28, 72-79.	1.0	6
12	Influenza and Respiratory Virus Surveillance, Vaccine Uptake, and Effectiveness at a Time of Cocirculating COVID-19: Protocol for the English Primary Care Sentinel System for 2020-2021. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e24341.	1.2	22
13	UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records. <i>BMC Public Health</i> , 2021, 21, 484.	1.2	25
14	SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). <i>Lancet, The</i> , 2021, 397, 1459-1469.	6.3	557
15	COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. <i>Lancet, The</i> , 2021, 397, 1725-1735.	6.3	658
16	Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. <i>New England Journal of Medicine</i> , 2021, 385, 585-594.	13.9	2,411
17	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. <i>Lancet, The</i> , 2021, 398, 856-869.	6.3	430
18	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. <i>Lancet, The</i> , 2021, 398, 2258-2276.	6.3	519

#	ARTICLE	IF	CITATIONS
19	Excess mortality in the first COVID pandemic peak: cross-sectional analyses of the impact of age, sex, ethnicity, household size, and long-term conditions in people of known SARS-CoV-2 status in England. <i>British Journal of General Practice</i> , 2020, 70, e890-e898.	0.7	51
20	Disparities in the excess risk of mortality in the first wave of COVID-19: Cross sectional study of the English sentinel network. <i>Journal of Infection</i> , 2020, 81, 785-792.	1.7	36
21	Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1034-1042.	4.6	493
22	Infant Hospitalizations and Fatalities Averted by the Maternal Pertussis Vaccination Program in England, 2012-2017: Post-implementation Economic Evaluation. <i>Clinical Infectious Diseases</i> , 2020, 71, 1984-1987.	2.9	14
23	Emergence of a Novel Coronavirus (COVID-19): Protocol for Extending Surveillance Used by the Royal College of General Practitioners Research and Surveillance Centre and Public Health England. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e18606.	1.2	66
24	Chronic hepatitis B virus case-finding in UK populations born abroad in intermediate or high endemicity countries: an economic evaluation. <i>BMJ Open</i> , 2019, 9, e030183.	0.8	9
25	Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol). <i>BMJ Open</i> , 2019, 9, e029538.	0.8	30
26	Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data. <i>Journal of Viral Hepatitis</i> , 2019, 26, 541-551.	1.0	34
27	Haemophilus influenzae type b (Hib) seroprevalence and current epidemiology in England and Wales. <i>Journal of Infection</i> , 2018, 76, 335-341.	1.7	22
28	Cost-effectiveness analysis of maternal immunisation against group B Streptococcus (GBS) disease: A modelling study. <i>Vaccine</i> , 2018, 36, 7033-7042.	1.7	20
29	Sustained Effectiveness of the Maternal Pertussis Immunization Program in England 3 Years Following Introduction. <i>Clinical Infectious Diseases</i> , 2016, 63, S236-S243.	2.9	223
30	Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. <i>Journal of Hepatology</i> , 2016, 65, 17-25.	1.8	157
31	Enter B and W: two new meningococcal vaccine programmes launched. <i>Archives of Disease in Childhood</i> , 2016, 101, 91-95.	1.0	94
32	Attitudes to immunisation in pregnancy among women in the UK targeted by such programmes. <i>British Journal of Midwifery</i> , 2015, 23, 566-573.	0.1	33
33	A Case-Control Study to Estimate the Effectiveness of Maternal Pertussis Vaccination in Protecting Newborn Infants in England and Wales, 2012-2013. <i>Clinical Infectious Diseases</i> , 2015, 60, 333-337.	2.9	328
34	Group B meningococcal vaccine: recommendations for UK use. <i>Lancet</i> , The, 2014, 383, 1103-1104.	6.3	24
35	Effectiveness of maternal pertussis vaccination in England: an observational study. <i>Lancet</i> , The, 2014, 384, 1521-1528.	6.3	593
36	Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: Modelling the predicted impact of treatment under different scenarios. <i>Journal of Hepatology</i> , 2014, 61, 530-537.	1.8	76

#	ARTICLE	IF	CITATIONS
37	Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. <i>European Journal of Public Health</i> , 2012, 22, 187-192.	0.1	79
38	Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. <i>Lancet Neurology</i> , The, 2012, 11, 774-783.	4.9	165
39	Economic evaluation of infant and adolescent hepatitis B vaccination in the UK. <i>Vaccine</i> , 2011, 29, 466-475.	1.7	40
40	Prevention of perinatal transmission of hepatitis B to babies at high risk: an evaluation. <i>Vaccine</i> , 2005, 23, 5500-5508.	1.7	21
41	Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995â€“2000: implications for immunisation policy. <i>Journal of Clinical Virology</i> , 2004, 29, 211-220.	1.6	149
42	Control of hepatitis B in the United Kingdom. <i>Vaccine</i> , 1998, 16, S52-S55.	1.7	36
43	Surveillance for Viral Hepatitis. , 0, , 187-200.		1